Carna Biosciences, Inc.

Equities

4572

JP3220550002

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
408 ^JPY	-3.32%		-4.67%	-21.84%

Mar. 07	Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement	CI
2023	Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020

February 12, 2021 at 05:51 am EST

Carna Biosciences, Inc. provided consolidated earnings guidance for the full year ending December 31, 2020. The company expects net sales of JPY 923 million, operating loss of JPY 1,811 million, loss attributable to shareholders of the parent company of JPY 1,825 million or JPY 147.19 per share.

Latest news about Carna Biosciences, Inc.

Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement	Mar. 07	CI
Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.	22-12-07	CI
Carna Biosciences, Inc. announced that it expects to receive Ã‘11.209315 million in funding from Cantor Fitzgerald & Co.	22-11-21	CI
Carna Biosciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	22-05-09	CI
Brickell Biotech Obtains Exclusive Rights to Carna Biosciences' Inhibitor Portfolio Targeting Inflammatory Diseases	22-02-02	MT
Brickell Biotech, Inc. Enters into an Exclusive License Agreement with Carna Biosciences, Inc	22-02-02	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	21-08-05	CI
Carna Biosciences, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2021	21-08-05	CI
Carna Biosciences, Inc. announced that it has received ¥14.67507 million in funding from Cantor Fitzgerald & Co.	21-07-29	CI
Carna Biosciences, Inc. announced that it expects to receive ¥14.67507 million in funding from Cantor Fitzgerald & Co.	21-07-13	CI
Carna Biosciences, Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020	21-02-12	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	21-02-12	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020	20-11-08	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	20-11-08	CI
Carna Biosciences, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020	20-05-12	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2020	20-05-12	CI
Carna Biosciences, Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	20-02-07	CI
Carna Biosciences, Inc. Provides Earnings Forecast for the Fiscal Year Ending December 31, 2019	20-01-09	CI
Open Orphan Signs Contract with Carna Bioscience	19-11-18	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2019	19-11-07	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending December 31, 2019	19-08-12	CI
Carna Biosciences, Inc. announced that it has received ¥13.41925 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	19-07-28	CI
Carna Biosciences, Inc. announced that it expects to receive ¥13.41925 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	19-07-10	CI
Gilead Sciences, Inc. and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies	19-06-24	CI

Chart Carna Biosciences, Inc.

Duration

Period

More charts

Company Profile

Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release

More about the company

	1st Jan change	Capi.
CARNA BIOSCIENCES, INC.	-21.84%	45.75M
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
BIO-TECHNE CORPORATION	+0.17%	12.15B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research